Press Release Details

Vaxart to Present at the H.C. Wainwright 21st Annual Global Investment Conference

September 4, 2019 at 8:00 AM EDT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 4, 2019-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company update and overview at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019, at 12:30 p.m. EST in New York.

A live webcast of the presentation will be available in the Investors section of Vaxart’s website at A replay of the webcast will be archived on Vaxart’s website for 30 days following the presentation.

About Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart’s vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit

Source: Vaxart, Inc.

Daniella Funaro
Stern Investor Relations